Cost-effectiveness of positron emission tomography-CT in the evaluation of cancer of unknown primary of the head and neck

被引:9
作者
Smith, Kristine A. [1 ]
Dort, Joseph C. [1 ]
Hall, Stephen F. [2 ]
Rudmik, Luke [1 ]
机构
[1] Univ Calgary, Div Otolaryngol Head & Neck Surg, Dept Surg, Calgary, AB T2N 2T9, Canada
[2] Queens Univ, Queens Canc Res Inst, Div Canc Care & Epidemiol, Dept Otolaryngol Head & Neck Surg, Kingston, ON K7L 3N6, Canada
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2015年 / 37卷 / 12期
关键词
cost-effectiveness; positron emission tomography-CT; head and neck cancer; squamous cell carcinoma; unknown primary; SQUAMOUS-CELL CARCINOMA; LYMPH-NODE METASTASES; COMPUTED TOMOGRAPHY; PRIMARY TUMOR; CONVENIENT APPROXIMATION; DIAGNOSTIC EVALUATION; LIFE EXPECTANCY; PRIMARY SITE; WORK-UP; MANAGEMENT;
D O I
10.1002/hed.23830
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. Positron emission tomography (PET)-CT is a useful diagnostic adjunct for cancer unknown primary (CUP) of the head and neck; however, the increased cost has not been justified with an economic evaluation in this patient population. Methods. A decision tree analysis was performed from the perspective of the third party payer. Primary outcome was cost per life year gained ($/LYG). The 2 comparative groups were: (1) PET-CT followed by panendoscopy versus (2) panendoscopy alone. Results. The incremental cost-effectiveness ratios for N1, N2, and N3 CUP were $369.83/LYG, $329.43/LYG, and $4900.28/LYG, respectively. The sensitivity analysis demonstrated a 96.8%, 97.1%, and 60.1% certainty that PET-CT is cost-effective for CUP with N1, N2, and N3 disease, respectively. Conclusion. The use of PET-CT in patients with N1 and N2 CUP is the cost-effective choice. The cost-effectiveness in N3 CUP is questionable and should be used on an individual case basis. (C) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:1781 / 1787
页数:7
相关论文
共 43 条
  • [1] Cancer of unknown primary: Does treatment modality make a difference?
    Balaker, Ashley E.
    Abemayor, Elliot
    Elashoff, David
    St John, Maie A.
    [J]. LARYNGOSCOPE, 2012, 122 (06) : 1279 - 1282
  • [2] A CONVENIENT APPROXIMATION OF LIFE EXPECTANCY (THE DEALE) .1. VALIDATION OF THE METHOD
    BECK, JR
    KASSIRER, JP
    PAUKER, SG
    [J]. AMERICAN JOURNAL OF MEDICINE, 1982, 73 (06) : 883 - 888
  • [3] A CONVENIENT APPROXIMATION OF LIFE EXPECTANCY (THE DEALE) .2. USE IN MEDICAL DECISION-MAKING
    BECK, JR
    PAUKER, SG
    GOTTLIEB, JE
    KLEIN, K
    KASSIRER, JP
    [J]. AMERICAN JOURNAL OF MEDICINE, 1982, 73 (06) : 889 - 897
  • [4] Ensuring the Fiscal Sustainability of Health Care Reform
    Chernew, Michael E.
    Sabik, Lindsay
    Chandra, Amitabh
    Newhouse, Joseph P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (01) : 1 - 3
  • [5] Diagnostic Evaluation of Squamous Cell Carcinoma Metastatic to Cervical Lymph Nodes From an Unknown Head and Neck Primary Site
    Cianchetti, Marco
    Mancuso, Anthony A.
    Amdur, Robert J.
    Werning, John W.
    Kirwan, Jessica
    Morris, Christopher G.
    Mendenhall, William M.
    [J]. LARYNGOSCOPE, 2009, 119 (12) : 2348 - 2354
  • [6] Danielsen M, 2014, AM J NUCL MED MOLEC, V4, P17
  • [7] Dong MJ, 2008, NUCL MED COMMUN, V29, P791, DOI 10.1097/MNM.0b013e328302cd26
  • [8] Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions
    Fenwick, E
    O'Brien, BJ
    Briggs, A
    [J]. HEALTH ECONOMICS, 2004, 13 (05) : 405 - 415
  • [9] Fireman BH, 1997, HEALTH CARE FINANC R, V18, P51
  • [10] Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients
    Fleming, Alfred J., Jr.
    Smith, Stephen P., Jr.
    Paul, Christopher M.
    Hall, Nathan C.
    Daly, Brett T.
    Agrawal, Amit
    Schuller, David E.
    [J]. LARYNGOSCOPE, 2007, 117 (07) : 1173 - 1179